Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibromun - Philogen

Next Previous
Drug Profile

Fibromun - Philogen

Alternative Names: L19 TNF fusion protein; L19-hTNF; L19-TNF; L19-TNF-alpha; L19TNFALFA; Onfekafusp alfa; onfekafusp alpha

Latest Information Update: 17 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Philogen
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Phase II Glioblastoma; Glioma; Leiomyosarcoma
  • No development reported Colorectal cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 04 Feb 2025 Philogen completes enrollment of phase III trials in Soft tissue sarcoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Italy, France, Poland and Germany (IV)
  • 05 Apr 2024 Philogen withdraws the planned phase-IGLIOASTRA trial in Glioblastoma (Combination-therapy) (IV, Infusion), prior to enrollment initiation since the Sponsor had no further plan for the study in object (NCT05304663)
  • 20 Feb 2024 Philogen plans a phase II trial for Glioblastoma in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top